Interpace Biosciences, Inc.

OTCPK:IDXG Stok Raporu

Piyasa değeri: US$10.8m

Interpace Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Interpace Biosciences has a total shareholder equity of $-12.5M and total debt of $6.8M, which brings its debt-to-equity ratio to -54.3%. Its total assets and total liabilities are $13.0M and $25.5M respectively. Interpace Biosciences's EBIT is $4.4M making its interest coverage ratio 5. It has cash and short-term investments of $2.0M.

Anahtar bilgiler

-54.3%

Borç/özkaynak oranı

US$6.78m

Borç

Faiz karşılama oranı5x
NakitUS$2.02m
Eşitlik-US$12.49m
Toplam yükümlülüklerUS$25.46m
Toplam varlıklarUS$12.97m

Son finansal sağlık güncellemeleri

Recent updates

Interspace Biosciences trades high, appoints new finance chief

Feb 04

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Feb 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Uzun Vadeli Yükümlülükler: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IDXG has negative shareholder equity, which is a more serious situation than a high debt level.

Borcun Azaltılması: IDXG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Borç Kapsamı: IDXG's debt is well covered by operating cash flow (52.9%).

Faiz Kapsamı: IDXG's interest payments on its debt are well covered by EBIT (5x coverage).


Bilanço


Sağlıklı şirketleri keşfedin